www.progen.de

Hyperphage

Hyperphage - a helperphage with improved panning efficiency in phage display

An Effective Tool for the Isolation of Recombinant Antibodies, Proteins or Peptides from Hyperphage-Packed Libraries.

Introduction

A helper phage technology ("Hyperphage System") was developed by Rondot et al. (Nature Biotechnology 19:75-81, 2001). The Hyperphage System allows to improve antibody presentation in phage display by increasing the number of antibodies displayed per phage particle (up to 5 vs. 0.01) and thereby the system offers great advantage in the fields of functional gene analysis and proteomics. Panning of phages can be performed with small amounts of antigen and higher efficiency. For example, the application of universal libraries for antibody isolation can be improved by employing panning of hyperphage-packed libraries on blots of protein spots after 2-dimensional gel electrophoresis.

More Applications

Large numbers of open reading frames (ORFs) can be analyzed by panning against synthetic membrane- bound peptide epitopes. In cancer research, the hyperphage-packed library could be a tool to discover new tumour markers by panning against cellular surfaces.

The Hyperphage System

Hyperphages carry a deletion in the pIII gene. They are generated by an E. coli packaging cell line producing functional pIII which is used to package a phage genome with a pIII deletion. The resulting hyperphages carry functional pIII on their surface but lack the pIII gene in their genome. These hyperphages can then be used to infect bacteria with a phagemid library. Each of the resulting display phages carries several copies of the antibody or peptide on its surface, thus dramatically increasing panning efficiency.

Example with pSEX Phagemid Antibody Gene Library

Antigen binding was enhanced by more than two orders of magnitude by using hyperphage. Further, since the antibody carrying plasmid (phagemid) encodes a protease cleavage site between pIII and scFv fragment, the hyperphage-packed library can be eluted by protease treatment, allowing to elute the highest affinity binders, plus restoring wild-type infectivity phenotype to optimize the recovery of the antibody gene of interest.

Advantage
  • increases panning efficiency
  • allows panning with reduced amount of panning antigen
  • identifies high and low affinity binders

 

References

Protocols

  • Hust M., Frenzel, A., Tomszak, F, Kügler, J & Dübel, S. (2014) Antibody Phage Display. In: Dübel, S. & Reichert, J.M. (eds.) Handbook of Therapeutic Antibodies, 2nd ed. Wiley-VCH, Weinheim, ISBN 978-3-527-32937-3 p. 43-76
  • Hust, M., Frenzel, A., Schirmann, T. and Dübel, S. (2014) Selection of recombinant antibodies from antibody gene libraries. Methods Mol Biol. 1101, 305-320.2
  • Hust, M., Frenzel, A., Meyer, T., Schirmann, T. and Dübel, S. (2012). Construction of human naive antibody gene libraries. In: Antibody Engineering: Methods and Protocols, Ed: Chames, P., Meth Mol Biol 907, 85-107
  • Breitling, F., Broders, O., Helmsing, S., Hust, M & Dübel, S (2010) Improving phage display throughput by using Hyperphage, miniaturised titration and pVIII (g8p) ELISA. In: Antibody Engineering (2nd ed) Springer Protocols. Vol. 1, ISBN 978-3-642-01143-6, p. 197-206
  • Broders, O., Breitling, F., and Dübel, S. (2003). Hyperphage - Improving Antibody Presentation in Phage Display. Methods Mol Biol 205, 295-302.

 

Original papers on the successful use of the hyperphage system

  • Zantow J et al. (2016). Sci. Rep. 6:34337, DOI:10.1038/srep34337
  • Connor DO et al. (2016). PLoS One. Feb 9;11(2):e0148986. doi: 10.1371/journal.pone.0148986 114
  • Derman Y et al. (2016). Toxins 8:25
  • Rohrbeck A et al. (2016). Toxins 8:100
  • Miethe S et al. (2016). PLoS ONE 11:e0161446
  • Blokzijl A. et al. (2016). Mol Cell Proteomics 15:1848-1856
  • Kibat J et al. (2016). N. Biotech. 33:574-581
  • Rasetti-Escargueil C et al. (2015). mAbs 6:1161-1177
  • Miethe S et al. (2015). PLoS ONE 10:e0139905
  • Becker M et al. (2015). BMC Biotechnology 15:43
  • Avril A et al. (2015). BMC Biotechnology 15:86
  • Droste P et al. (2015).BMC Biotechnol.15:57
  • Zehner M et al. (2015). Immunity 42:850-863
  • Kügler J et al. (2015). BMC Biotechnol. 15:10
  • Fuchs M et al. (2014). BMC Biotechnol. 14:68
  • Hülseweh B et al. (2014). mAbs 6:717-726
  • Trott M et al. (2014). PLoS ONE 9:e97478
  • Miethe S et al. (2014). STO Scientific Publications, STO-MP-HFM239-16
  • Miethe S et al. (2014). mAbs 6:446-459
  • Schirrmann T et al. (2014). mAbs, J6(2)
  • Steinwand M et al. (2013). mAbs, 6:204-218     
  • Zhou M et al. (2013). Eur J immunol, 43:499-509
  • Meyer T et al. (2012). BMC Biotechnol, 12:29
  • Wezler X et al. (2012). Hum. Antibod. 21:13-28
  • Rülker T et al. (2012). PLoS ONE, 7(5):e37242. doi:10.1371/journal.pone.0037242
  • Zhang C. et al. (2012). PLoS ONE 7(1): e30684. doi:10.1371/journal.pone.0030684
  • Colwill K et al. (2011). Nature Meth. 8:551–558
  • Hust M et al. (2011). J. Biotechnol. 152:159-170
  • Meyer T et al. (2010). Vet. Microbiol. 147:162-169
  • Mersmann M et al. (2010). N. Biotec, 27:118-128
  • Schütte M et al. (2009). PLoS ONE 4:e6625
  • Pelat T et al. (2009). BMC Biotechnol., 9:60
  • Naseem S et al. (2010). Veterinary Microbiology 142:285-292
  • Kirsch MI et al. (2008). BMC-Biotechnol. 8:66
  • Kügler J et al. (2008). Applied Microbiology and Biotechnology 80:447- 458
  • Thie H et al. (2008). N Biotechnol. 5:49-54
  • Pelat T et al. (2007). Antimicrob agents and chemother 51:2758-2764
  • Soltes G et al. (2007). J Biotech 127:626-637
  • Hust M et al. (2006). Bio/Techniques, 41:335-342
  • Kirsch M et al. (2005). J immunol Meth 301:173-185
  • Rondot S et al. (2001). Nature Biotechnol. 19:75-78